ALVOWAlvotech Warrant
0.2201USDMkt Cap: —P/E: —3d ago
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)494.61M $
Gross Profit350.76M $
Net Income (TTM)27.92M $
Revenue/Share1.675 USD
Last Price0.2201 USD
Fiscal Year End—
MR Quarter—
Employees1.3K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.24
EPS (TTM)—
EPS (Forward)—
52W Range
0.22010% of range0.2300
52W High0.2300 USD
52W Low0.2201 USD
Profitability
Gross Margin59.82%
Oper. Margin-11.05%
EBITDA Margin15.31%
Profit Margin4.76%
ROE-9.81%
ROA1.88%
Growth
Revenue Growth-38.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.20M $
CapEx (TTM)96.13M $
FCF Margin-24.89%
FCF Yield—
Net Debt1.31B $
Net Debt/EBITDA17.28
Balance Sheet
Debt/Equity-5.09
Current Ratio1.65
Quick Ratio0.79
Book Value/Sh-0.9120 USD
Cash/Share0.4000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float140.79M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.18
S&P 52W Chg19.18%
Avg Vol (30d)1.81K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—